Welcome to our dedicated page for HARVARD BIOSCIENCE SEC filings (Ticker: HBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harvard Bioscience filings document regulatory disclosures for a life science research tools company with Cellular and Molecular Technologies and Preclinical product families. Form 8-K reports cover operating results, preliminary financial information, corporate presentations, restructuring and manufacturing consolidation actions, executive employment agreements, and stockholder votes affecting the company’s common stock.
Proxy statements describe board matters, executive compensation, pay-versus-performance data, equity awards, charter amendments and special-meeting proposals, including reverse stock split authority and related voting results. The filings also frame governance, capital-structure and forward-looking disclosure topics tied to the company’s global sales channels and manufacturing footprint.
Harvard Bioscience (HBIO) – Form 4 filing
Director Seth B. Benson reported the grant of 110,000 restricted stock units (RSUs) on 16-Jul-2025. The RSUs were awarded at a price of $0.00 and will fully vest on the earlier of the company’s next Annual Meeting after 16-Jul-2025 or on 16-Jul-2026.
Following the grant, Benson beneficially owns 110,000 common shares, held directly. No derivative securities, option exercises or share sales were disclosed. The transaction reflects routine director equity compensation and does not signal any change to Harvard Bioscience’s operating outlook or capital structure beyond a modest increase in outstanding shares.
Harvard Bioscience (HBIO) filed an amended Form 8-K to restate Item 3.01 and confirm that Nasdaq has formally determined the company is out of compliance with Listing Rule 5605(c)(2)(A), which requires at least three independent directors on the audit committee. The shortfall was triggered by director Alan Edrick’s resignation on 10 Jun 2025, leaving only two audit-committee members. Nasdaq’s notice was received on 26 Jun 2025.
HBIO states it will appoint a new, fully independent director “as expeditiously as practicable” and will rely on the cure period in Rule 5605(c)(4), giving the company until the earlier of its next annual shareholders’ meeting or 10 Jun 2026 to regain compliance. Until then, the company remains subject to potential delisting if it fails to add a qualified director within the allowed timeframe. No financial statements, earnings metrics or transactional details were included in this filing.